Cediranib
Cediranib[edit]
Cediranib is a potent small molecule inhibitor of vascular endothelial growth factor (VEGF) receptors, primarily used in the treatment of certain types of cancer. It is an oral medication that targets the VEGF receptor tyrosine kinases, which play a crucial role in angiogenesis, the process by which new blood vessels form from pre-existing vessels. By inhibiting these receptors, Cediranib can reduce the blood supply to tumors, thereby inhibiting their growth.
Mechanism of Action[edit]
Cediranib works by selectively inhibiting the activity of VEGF receptors 1, 2, and 3. These receptors are critical for the signaling pathways that promote angiogenesis. By blocking these pathways, Cediranib effectively reduces the proliferation and migration of endothelial cells, which are essential for new blood vessel formation. This action starves tumors of the necessary nutrients and oxygen supplied by the blood, leading to reduced tumor growth and potential tumor shrinkage.
Clinical Uses[edit]
Cediranib has been investigated for use in various types of cancer, including ovarian cancer, colorectal cancer, and non-small cell lung cancer. It is often studied in combination with other chemotherapeutic agents to enhance its efficacy. Clinical trials have shown that Cediranib can improve progression-free survival in patients with certain cancers, although its use is associated with some adverse effects.
Side Effects[edit]
The use of Cediranib can lead to several side effects, which are common with VEGF inhibitors. These include hypertension, fatigue, diarrhea, and hand-foot syndrome. More serious side effects can include thromboembolic events, gastrointestinal perforations, and hemorrhage. Patients receiving Cediranib require careful monitoring for these potential adverse effects.
Research and Development[edit]
Cediranib is still under investigation in various clinical trials to better understand its efficacy and safety profile. Researchers are exploring its use in combination with other targeted therapies and immunotherapies to enhance its anti-tumor effects. Ongoing studies aim to identify biomarkers that can predict which patients are most likely to benefit from Cediranib treatment.
